Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

t data and treatment protocols every two years.

VELCADE has been available to patients, who have relapsed after a previous treatment, in the United States since 2003 and in Europe since 2004. VELCADE as a single agent shows a median overall survival in this patient population of two and a half years (29.8 months) with "robust response rates" regardless of age. VELCADE in combination with DOXIL(R) was approved in May 2007. Data from a follow-up to a Phase 3 multi-national clinical trial shows that this combination further improves the probability of survival by 41%. Among the findings presented from an open label Phase I/II study evaluating 54 patients, when VELCADE is combined with melphalan and prednisone in newly diagnosed patients who do not go on to have transplants, survival was 85% the strongest 3 year survival rate demonstrated to date.

REVLIMID, an oral drug, is the newest of the novel therapies. This is the first conference since its European approval earlier this month; it is already approved in the United States for use in combination with dexamethasone as a treatment for multiple myeloma in patients who have been previously treated. Among the findings presented, in patients who have relapsed or not responded to a previous treatment, the 35 month median survival using REVLIMID in combination with dexamethasone has been characterized as the "highest response rate and longest overall survival" reported so far from two large randomized controlled Phase III trials that enrolled more than 700 patients worldwide. Importantly, it was previously reported that in patients newly diagnosed with multiple myeloma, in a large randomized Phase III trial evaluating more than 400 patients, REVLIMID with low dose dexamethasone demonstrated what has been called an "unprecedented" 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over.

Combining these two powerful agents, VELCADE AND REVLIMID, produces "robust and du
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:7/31/2015)... CHAPEL HILL, N.C. , July 31, 2015 ... to product success in the biopharmaceutical market. Patients ... the process of selecting and switching therapies. This ... and is pushing marketers, efforts toward patient-focused marketing. ... to patient engagement, marketers have learned it,s important ...
(Date:7/31/2015)... , July 31, 2015 ... 2015 market research report that provides an overview ... using data sourced from in-house databases, secondary and ... and needles market products pipeline spread across 124 ... with 73 tables and 5 figures is now ...
(Date:7/31/2015)... Quietly, sedately, Morocco,s pharmaceutical sector is shining. ... is strong, with a well-developed base of local producers ... One place where the quality of Moroccan pharma ... quietly become the second largest African exporter of drugs ... Moroccan pharma companies have been making inroads as exporters ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3
... DUBLIN, June 28, 2011 ,   ... SHPGY ), the global specialty,biopharmaceutical company, announces that following ... the,waiting period under the Hart-Scott-Rodino Antitrust Improvements,Act of 1976, ... on May 17, 2011, has been completed. ...
... EXTON, Pa., June 28, 2011 Morphotek®, Inc., a ... commenced a multi-center phase II study of farletuzumab in ... lung cancer (NSCLC). The study will evaluate farletuzumab, a ... with the physician,s choice of one of three standard ...
Cached Medicine Technology:Shire Completes Acquisition of Advanced BioHealing, Inc. 2Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer 2Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer 3Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer 4
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers allows users to clarify, edit and delete any message including ones already ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic ... Grand Garden Arena. Fans of every genre of music will have an act they ... first day of the festival, the following artists will perform: Sam Smith, Coldplay, Kenny ...
(Date:7/31/2015)... (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 will emanate ... Football League’s biggest day each year is the Super Bowl. In the two weeks that ... place from the host venue. The 2016 Super Bowl game will mark the 50th time ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted ... in predictive health analytics , Jvion continues to disrupt the predictive analytic ... software that targets patient and population level illness to drive prevention and better ...
(Date:7/31/2015)... ... ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the newest applicator for ... applicator in the United States as an upgrade to the CoolSmooth applicator cleared by ... required a 2 hour treatment time. The new CoolSmooth Pro reduces the treatment ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Currently lie detection methods use heart activity, but now the ... detection reports the online edition of New Scientist. // ... Texas found that the heart is unreliable as it's affected ... as hormones, ,"But the gut has a mind of its ...
... polio. Only 30 cases have been reported till mid September this ... ,In the whole of 2004, there were only ... is expected to announce by the end of this year or ... ,Among the 30 cases, 16 have been reported from Uttar Pradesh, ...
... research in United Kingdom as part of ?145m package ... worldwide. Bill Gates along with his Melinda Gates Foundation ... malaria eradication over the next five years. Mr. Gates ... of AIDS and cancer, while malaria, which kills millions ...
... Mizoram the border state of the country has strictly ... its neighboring country Myanmar to combat the ongoing was ... a long (404-kms) international border with Myanmar and there ... Mr. C Sangnghina, The Director of State Animal Husbandry ...
... recent study was conducted to investigate the association among ... factors. The results indicate that diabetic women have a ... there is no relationship between osteoporosis and cardiovascular risk ... far been believed that Type II diabetics have bone ...
... A diet with high fat and sugar induces abnormalities in ... cells in the liver, according to a study of mice ... ,The study, published in the Oct. issue of the ... not only gained more weight, but also developed fatty livers ...
Cached Medicine News:Health News:Bill Gates to Fund ?28m for Malaria researc 2Health News:Diabetic Type II Women Have Elevated Bone Density Mass 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: